STAAR Surgical Company

STAA • Medical - Instruments & Supplies

$23.47

▼ -0.11 (-0.45%)

Current price

EarningsLatest report: Jul 3, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$1.21B

Growth

1.6%

Cash Flow

2/5

Trend

Volatile

Evidence

Manageable debt level · 0.11Healthy liquidity · 4.55Negative growth trendWeak profitability

Financial data as of: Jul 3, 2026, 12:00 AM UTCLast earnings update: Jul 3, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:09 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$23.47

Change-0.45%

Shares Out51.50M

Market Cap$1.21B

Enterprise Value$1.10B

52W Range15.59 - 35.87

Beta1.23

P/E314.86

P/S3.56

P/B3.31

P/FCF-207.97

EV/Sales3.23

Price$23.47

Change-0.45%

Shares Out51.50M

Market Cap$1.21B

Enterprise Value$1.10B

52W Range15.59 - 35.87

Beta1.23

P/E314.86

P/S3.56

P/B3.31

P/FCF-207.97

EV/Sales3.23

EV/EBITDA23.01

EV/FCF-188.59

Earnings Yield0.32%

FCF Yield-0.48%

Dividend Yield0.00%

Gross Margin76.19%

Oper. Margin-19.19%

Profit Margin-33.60%

Debt/Eq0.11

Current Ratio4.55

Quick Ratio3.74

Revenue 5Y1.57%

Target$31.50

Target Upside34.21%

Target Median$31.50

Target Range27.00 - 40.00

Volume1.84M

Avg Volume965.84K

EPS Surprise0.33

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

69/100

Why this score▼

Manageable debt level · 0.11Healthy liquidity · 4.55Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

STAA

Analyst sentiment

Based on 16 analyst votes · 2026-09-04

56/100

Neutral

Bullish

Hold

Bearish

Price Target

2026-08-14

Low

$19.00

Mean

$30.38

Median

$31.50

High

$40.00

Company Overview

IPO: 2/24/1992

Industry: Medical - Instruments & Supplies

P/B i: 3.31

Debt / Equity i: 0.11

Operating Margin: -19.19%

Net Margin: -33.60%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.11

Current Ratio: 4.55

Quick Ratio: 3.74

Status: Good

Insider Transactions

Recent executive and insider activity

ANDREWS DEBORAH J

Transaction: 07/31/2026

SELL

Change

-20,787

Price

Not reported

Filing

08/04/2026

Type

SELL

ANDREWS DEBORAH J

Transaction: 07/31/2026

SELL

Change

-10,576

Price

$24.36

Filing

08/04/2026

Type

SELL

Foust Warren

Transaction: 07/31/2026

SELL

Change

-20,787

Price

Not reported

Filing

08/04/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
ANDREWS DEBORAH J	SELL	-20,787	Not reported	07/31/2026	08/04/2026
ANDREWS DEBORAH J	SELL	-10,576	$24.36	07/31/2026	08/04/2026
Foust Warren	SELL	-20,787	Not reported	07/31/2026	08/04/2026
Foust Warren	SELL	-10,576	$24.36	07/31/2026	08/04/2026
ANDREWS DEBORAH J	SELL	-13,955	Not reported	06/25/2026	08/04/2026
ANDREWS DEBORAH J	SELL	-6,480	$31.21	06/25/2026	08/04/2026
Wang Christopher Min Fang	BUY	+11,145	$29.12	06/18/2026	06/23/2026
Jiang Wei	SELL	-10,683	Not reported	06/18/2026	06/22/2026
Jiang Wei	BUY	+10,683	Not reported	06/18/2026	06/22/2026
SILVERMAN LOU	SELL	-10,683	Not reported	06/18/2026	06/22/2026
SILVERMAN LOU	BUY	+10,683	Not reported	06/18/2026	06/22/2026
Zhou Lilian Yansheng	BUY	+3,091	Not reported	06/18/2026	06/22/2026
Zhou Lilian Yansheng	BUY	+5,572	$29.12	06/18/2026	06/22/2026
Butcher Arthur C	SELL	-5,341	Not reported	06/18/2026	06/22/2026
Butcher Arthur C	BUY	+4,458	$29.12	06/18/2026	06/22/2026
Butcher Arthur C	BUY	+5,341	Not reported	06/18/2026	06/22/2026
Bradsher Neal C	BUY	+11,145	$29.12	06/18/2026	06/22/2026
LeBuhn Richard T.	BUY	+11,145	$29.12	06/18/2026	06/22/2026
Zhou Lilian Yansheng	BUY	+3,530	$28.29	06/12/2026	06/15/2026
Michna Magda	BUY	+10,997	Not reported	05/15/2026	05/19/2026

About the Company

STAAR Surgical Company

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

Source - link

Peers

AZTA BBNX BLFS KMTS NVCR ORIC PGEN PLSE TERN TRML

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

STAAR Surgical Names Medtech Innovator and Platform Builder Ben Park as Chief Technology Officer

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR's Executive Committee and report to Warren Foust, President and Chief Executive Officer. "Evolving STAAR from a single-product focus into a multi-product platform is cent.

Business Wire

American Capital Management Inc. Makes New $24.29 Million Investment in STAAR Surgical Company $STAA

American Capital Management Inc. purchased a new stake in STAAR Surgical Company (NASDAQ: STAA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 846,659 shares of the medical instruments supplier's stock, valued at approximately $24,291,000. American Capital Management Inc.

Defense World

Deciphering Staar Surgical (STAA) International Revenue Trends

Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks Investment Research

Staar Surgical Co (STAA) Shares Surge 3.4% -- What GF Score of 80 Tells Investors

On August 14, 2026, Staar Surgical Co (STAA) shares rose 3.4% today, bringing the current price to $26.19. The stock has fluctuated within a 52-week range of $1

GuruFocus

STAAR Surgical Q2 Earnings Call Highlights

STAAR Surgical NASDAQ: STAA reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier, as growth in China, the Americas and parts of Europe contributed to what President and Chief Executive Officer Warren Foust called the company's strongest first half of revenue performance.

MarketBeat

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-13	0.05422	0.38	0.32578
2026-03-03	0.18	-0.2	-0.38
2025-11-05	0.18	0.46	0.28
2025-08-06	-0.56	-0.07	0.49
2025-05-07	-0.59	-0.52	0.07
2025-02-11	0.02	-0.5	-0.52
2024-10-30	0.19	0.37	0.18
2024-08-07	0.25	0.33	0.08
2024-05-07	0.05	0.06	0.01
2024-02-26	0.19	0.24	0.05
2023-11-01	0.2	0.3	0.1
2023-08-02	0.32	0.4	0.08